Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.

Abstract excerpt

IntroductionClinical prediction models for response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung cancer (NSCLC) with bone metastasis (BoM) and EGFR mutations are lacking. This study evaluated predictors of response to the EGFR-TKI icotinib in patients with NSCLC and BoM.MethodsWe retrospectively analysed patients with EGFR-mutated...

Topics

Join the communities discussing this publication.

• Bone Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Crown Ethers
• ErbB Receptors
• Nomograms